Key result
IV inotropes, tasosartan, and eptifibatide headlined the January 1998 FDA advisory panel meeting.
Why the study?
Evaluation of intravenous inotropic agents in heart failure, liver function abnormalities with tasosartan, and use of eptifibatide in acute cardiac ischemia required regulatory discussion.
Key points are not available for this paper at this time.
Design
FDA Cardiovascular and Renal Advisory Panel meeting
Summary of the January 1998 FDA Cardiovascular and Renal Advisory Panel meeting discussing inotropes for heart failure, tasosartan hepatotoxicity, and eptifibatide for acute cardiac ischemia.
T he Cardiovascular and Renal AdvisoryPanelof the FDA met January 27-28, 1998, to discuss (1) evaluation and use of intravenous inotropic agents in patients with heart failure; (2) liver function test abnormalities with a new AT 1 receptor blocker, tasosartan; and (3) the use of the platelet IIb/IIIa receptor blocker eptifibatide in syndromes of acute cardiac ischemia.
No takes yet. Share an insight, caveat, or question.
Thadani et al. (1998) studied this question. Intravenous inotropes, the AT1 receptor blocker tasosartan, and the platelet IIb/IIIa receptor blocker eptifibatide were the primary topics of the January 1998 FDA advisory panel meeting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: